<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180813">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00740870</url>
  </required_header>
  <id_info>
    <org_study_id>G050186</org_study_id>
    <nct_id>NCT00740870</nct_id>
  </id_info>
  <brief_title>Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original IDE Cohort</brief_title>
  <acronym>Melody IDE</acronym>
  <official_title>Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional RVOT Conduits: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to confirm the long-term functionality of implantation of the
      Medtronic Melody TPV at 5 years is no worse than the historical control established through
      literature review. The secondary objectives are to assess safety, procedural success, and
      clinical utility of transcatheter implantation of the Melody TPV.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-Term Functionality of Melody</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Procedural Success</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Adverse Events</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Device-related Adverse Events</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter Re-intervention on TPV</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Replacement of the RVOT Conduit</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all-cause, procedural and device-related)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment (NYHA Classification)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Congenital Heart Defects</condition>
  <condition>Dysfunctional Right Ventricular Outflow Tract Conduits</condition>
  <arm_group>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Pulmonary Valve replacement</intervention_name>
    <description>Transcatheter valve implantation into a RVOTconduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.</description>
    <arm_group_label>Melody TPV Implant</arm_group_label>
    <other_name>Melody Transcatheter Pulmonary Valve</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 5 years of age

          -  Weight greater than or equal to 30 kilograms

          -  Existence of a full (circumferential) RVOT conduit that was equal to or greater than
             16mm in diameter when originally implanted, or a stented bioprosthesis with a rigid
             circumferential sewing ring in the RVOT that has an internal diameter greater than or
             equal to 18mm and less than or equal to 22mm when originally implanted.

          -  Any of the following by transthoracic echocardiography:

          -  Patient in NYHA Classification II, III, or IV:

          -  Moderate (3+) or severe (4+) pulmonary regurgitation

          -  Mean RVOT gradient greater than or equal to 35mmHg

          -  Patients in NYHA Classification I:

          -  Severe (4+) pulmonary regurgitation with RV dilatation or dysfunction

          -  Mean RVOT gradient greater or equal to 40mmHg

        Exclusion Criteria:

          -  Active endocarditis

          -  Major or progressive non-cardiac disease (liver failure, renal failure, cancer)that
             has a life expectancy of less than one year

          -  Patient or guardian unwilling or unable to provide written informed consent or comply
             with follow-up requirements

          -  Obstruction of the central veins (including the superior and inferior vena cava,
             bilateral iliac veins) such that the delivery system cannot be advanced to the heart
             via transvenous approach from either femoral vein or internal jugular vein

          -  Positive urine or serum pregnancy test 24 hours prior to procedure in female patients
             of child bearing potential

          -  Known intravenous drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of NY-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3784</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's and Regional Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>August 21, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RVOT</keyword>
  <keyword>Dysfunctional</keyword>
  <keyword>conduit</keyword>
  <keyword>Indications</keyword>
  <keyword>Invasive</keyword>
  <keyword>intervention</keyword>
  <keyword>Tetralogy of Fallot</keyword>
  <keyword>Right Ventricular Outflow Tract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
